Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474091 | 0.86 | LMNA (0.48) | KDM4EGAARAB9AALOX5MAPT | |
| SCHEMBL95917 | 0.86 | RAB9A (0.56) | KDM4EGAARAB9AALOX5MAPT | |
| SCHEMBL3077683 | 0.86 | SMN1; SMN2 (0.56) | KDM4EGAARAB9AMAPTTP53 | |
| SCHEMBL11950421 | 0.84 | KDM4E (0.51) | KDM4EGAARAB9AALOX5MAPT | |
| SCHEMBL28295525 | 0.83 | ALOX5 (0.60) | ALOX5MAPTTP53LMNATHRB | |
| SCHEMBL3371906 | 0.83 | MAPT (0.55) | KDM4EGAARAB9AMAPTLMNA | |
| SCHEMBL1508353 | 0.82 | NPC1 (0.58) | KDM4EGAAMAPTFFAR1PPARD | |
| SCHEMBL2241995 | 0.82 | KDM4E (0.50) | KDM4EGAARAB9AALOX5MAPT | |
| SCHEMBL28178934 | 0.82 | KDM4E (0.50) | KDM4EGAARAB9AALOX5MAPT | |
| Hydrochloric Acid SCHEMBL4759944 | 0.81 | KDM4E (0.49) | KDM4EGAARAB9AALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184186-A1 | PROCESS FOR PREPARING LIGANDS OF PPARDELTA AND THE INTERMEDIATE COMPOUNDS FOR PREPARING THE SAME | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2011-07-28 | — | — | US | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184186-A1 | PROCESS FOR PREPARING LIGANDS OF PPARDELTA AND THE INTERMEDIATE COMPOUNDS FOR PREPARING THE SAME | PPARG, PPARD, PPARA | KDM4E 4310/4885GAA 1778/4885RAB9A 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.